Key facts
- It has raised $1.5M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Lanchi Ventures, AnlongMed, AptarGroup.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Sonmol
- ·The full record, as it builds
Funding rounds
No funding rounds for Sonmol are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sonmol
Developer of AI-powered digital platforms for respiratory disease diagnosis, treatment, and prognosis. The company's software enables asthma and COPD diagnosis through pathology-based disease models, supports remote follow-up and chronic disease management via mobile and micro-apps, and facilitates hierarchical treatment coordination between tertiary and primary hospitals, thereby improving care continuity and clinical efficiency.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2014
- Website
- ibreathcare.com/
- Ownership
- Privately Held (backing)
Sonmol doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sonmol shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sonmol in its N-PORT filings yet. We sweep new filings monthly.